| |
FTICR-MS discovery
|
MRM validation
|
|---|
| |
Genomics Collaborative
|
Seracare 1
|
Osaka
|
Chiba
|
Seracare 2
|
|---|
| |
CRC
|
Control
|
CRC
|
Control
|
CRC
|
Control
|
CRC
|
Control
|
CRC
|
Control
|
|---|
|
Total
|
40
|
50
|
26
|
25
|
46
|
35
|
40
|
40
|
70
|
70
|
|
Male
N
|
19
|
24
|
17
|
16
|
27
|
-
|
19
|
24
|
44
|
41
|
|
Male age
|
59 (30-78)
|
56 (30-78)
|
62 (46-80)
|
51 (35-70)
|
63 (28-90)
|
-
|
68 (45-91)
|
48 (36-69)
|
67 (39-87)
|
63 (32-82)
|
|
Male BMI
|
20.9 ± 3.8
|
25.0 ± 0.9
|
24.3 ± 5.7
|
25.6 ± 4.6
|
NA
|
-
|
NA
|
NA
|
28.0 ± 4.8
|
26. ± 4.2
|
|
Female N
|
21
|
26
|
9
|
9
|
19
|
-
|
21
|
16
|
26
|
29
|
|
Female age
|
54 (40-82)
|
55 (40-79)
|
78 (59-86)
|
55 (26-95)
|
65 (31-77)
|
-
|
70 (51-84)
|
49 (39-59)
|
73 (35-90)
|
56 (26-86)
|
|
Female BMI
|
19.9 ± 4.6
|
24.8 ± 2.2
|
23 ± 3.2
|
29 ± 8.0
|
NA
|
-
|
NA
|
NA
|
25.5 ± 4.4
|
24.0 ± 4.5
|
|
Stage 0/I
|
8
|
-
|
5
|
-
|
10
|
-
|
9
|
-
|
13
|
-
|
|
Stage II
|
16
|
-
|
8
|
-
|
14
|
-
|
18
|
-
|
21
|
-
|
|
Stage III
|
15
|
-
|
8
|
-
|
12
|
-
|
11
|
-
|
25
|
-
|
|
Stage IV
|
1
|
-
|
2
|
-
|
8
|
-
|
2
|
-
|
7
|
-
|
|
Unknown
|
0
|
-
|
3
|
-
|
2
|
-
|
0
|
-
|
4
|
-
|
- BMI = body mass index; CRC = colorectal cancer; FTICT-MS = Fourier transform ion cyclotron resonance mass spectroscopy; MRM = multiple reaction monitoring.
